Nine reasons why ecstasy is not quite what it used to be.
Jane Mounteney, Paul J Griffiths, Alessandra Bo, Andrew Cunningham, João Matias, Alessandro Pirona
International Journal of Drug Policy November 20, 2017 DOI: 10.1016/j.drugpo.2017.09.016 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Scoping study Peer reviewed |
|---|---|
| Topics | MDMA |
| Keywords | Humans Substance-related disorders N-methyl-3,4-methylenedioxyamphetamine Hallucinogens Social marketing Europe Emcdda |
| Key points | The paper argues that Europe's contemporary MDMA market differs from the 1990s ecstasy market in nine areas, including production innovation, precursor availability, online markets, competition from other stimulants and new psychoactive substances, high-strength MDMA availability, and more mainstream use. It proposes that today's MDMA is in some respects a 'third generation' product with a different consumer profile, implying that responses designed for the earlier market may need review and revamp. |
Abstract
This paper explores the recent resurgence in use of ecstasy/MDMA in Europe and highlights keys areas of continuity and divergence between the ecstasy market of the 1990s and the current MDMA market. Based on a scoping study involving a targeted multi-source data collection exercise on MDMA, it highlights nine areas that have undergone some level of change, linked with both supply and demand for the drug. Factors discussed include: innovation in production techniques; changes in precursor chemical availability; the role of online markets; competition with other stimulants and new psychoactive substances; the increased availability of high-strength MDMA; and the shift from subcultural towards more mainstream use of the drug. The paper proposes that the MDMA on Europe's contemporary market is in some respects a third generation product with a different consumer profile, with implications that responses developed at the time of the drug's earlier iteration, may be in need of a review and revamp.
Citations in the library
Cited by 12
- MDMA-related deaths in Australia 2000 to 2018. International Journal of Drug Policy December 19, 2019
- Profile and correlates of colorimetric reagent kit use among people who use ecstasy/MDMA and other illegal stimulants in Australia. International Journal of Drug Policy November 1, 2021
- Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand. Harm Reduction Journal March 21, 2024
- Increases in the use of drug testing kits among nightclub and festival attendees in New York City who use ecstasy, 2017-2022. Drug and Alcohol Review May 1, 2024
- A thematic analysis of MDMA-related harm and harm reduction experiences and knowledge in Aotearoa New Zealand. Harm Reduction Journal May 23, 2024
and 7 more in the library
Cites 5
- Instability of the ecstasy market and a new kid on the block: mephedrone Journal of Psychopharmacology September 8, 2010
- 'Surfing the Silk Road': a study of users' experiences. International Journal of Drug Policy November 1, 2013
- MDMA powder, pills and crystal: the persistence of ecstasy and the poverty of policy Drugs and Alcohol Today April 13, 2009
- Self-Reported Ecstasy/MDMA/"Molly" Use in a Sample of Nightclub and Dance Festival Attendees in New York City. Substance Use & Misuse September 23, 2016
- Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK. Emergency Medicine Journal August 19, 2010